Literature DB >> 28251255

[Side effects of erectile dysfunction drug treatment].

H Sperling1.   

Abstract

Due to the large number of drugs now available, the therapy of erectile dysfunction has changed profoundly in recent decades. The phosphodiesterase type 5 inhibitors (PDE5-i): sildenafil, taldalafil, vardenafil, and avanafil are EMA European Medicines Agency approved and show similar adverse events and success rates. The absolute contraindication is the simultaneous use of nitrates. Despite this wide variety of options, therapy of erectile dysfunction should be performed in an individually adapted manner. The exact patient's history, physical examination, collaboration of medical disciplines, and choice of therapy will offer every patient the possibility to achieve or regain a satisfying sexual life.

Entities:  

Keywords:  Combination therapy; Hypersensitivity; Mechanism of action; Monotherapy; Pharmacology

Mesh:

Substances:

Year:  2017        PMID: 28251255     DOI: 10.1007/s00120-017-0341-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

Review 1.  Current status of local penile therapy.

Authors:  F Montorsi; A Salonia; M Zanoni; P Pompa; A Cestari; G Guazzoni; L Barbieri; P Rigatti
Journal:  Int J Impot Res       Date:  2002-02       Impact factor: 2.896

2.  Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.

Authors:  R Shabsigh; H Padma-Nathan; M Gittleman; J McMurray; J Kaufman; I Goldstein
Journal:  Urology       Date:  2000-01       Impact factor: 2.649

3.  Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.

Authors:  Arthur L Burnett; Uzoma A Anele; Irene N Trueheart; John J Strouse; James F Casella
Journal:  Am J Med       Date:  2014-03-25       Impact factor: 4.965

Review 4.  [Sildenafil (Viagra). Tolerance, contraindications, drug interactions].

Authors:  H Sperling; M C Michel; H Rübben
Journal:  Urologe A       Date:  1999-03       Impact factor: 0.639

5.  Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors.

Authors:  A T Guay; J B Perez; J Jacobson; R A Newton
Journal:  J Androl       Date:  2001 Sep-Oct

Review 6.  IC351 (tadalafil, Cialis): update on clinical experience.

Authors:  H Porst
Journal:  Int J Impot Res       Date:  2002-02       Impact factor: 2.896

7.  Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial.

Authors:  Adelaide M Arruda-Olson; Douglas W Mahoney; Ajay Nehra; Marilyn Leckel; Patricia A Pellikka
Journal:  JAMA       Date:  2002-02-13       Impact factor: 56.272

8.  Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.

Authors:  Howard D Pomeranz; Kyle H Smith; William M Hart; Robert A Egan
Journal:  Ophthalmology       Date:  2002-03       Impact factor: 12.079

Review 9.  Topiglan MacroChem.

Authors:  Chris G McMahon
Journal:  Curr Opin Investig Drugs       Date:  2002-04

10.  Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease.

Authors:  Lucio Dell'Atti
Journal:  Urol Ann       Date:  2015 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.